{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:19:51Z","timestamp":1792484391889,"version":"4.5.0"},"reference-count":63,"publisher":"American Association for Cancer Research (AACR)","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":78,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["ECO202206015528"],"award-info":[{"award-number":["ECO202206015528"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006331","name":"Cancerop\u00f4le PACA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007492","name":"Fondation Bettencourt Schueller","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022184","name":"Institut Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022184","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013037","name":"Fondation des Treilles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013037","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019180","name":"HORIZON EUROPE European Research Council","doi-asserted-by":"publisher","award":["TargetSWitch 101077864"],"award-info":[{"award-number":["TargetSWitch 101077864"]}],"id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur le Cancer","doi-asserted-by":"publisher","award":["PGA1-RF20190208576"],"award-info":[{"award-number":["PGA1-RF20190208576"]}],"id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["INCa-DGOS-Inserm_12551 SIRIC2 and INCa-DGOS-Inserm-ITMO Cancer_18002 SIRIC EpiCURE"],"award-info":[{"award-number":["INCa-DGOS-Inserm_12551 SIRIC2 and INCa-DGOS-Inserm-ITMO Cancer_18002 SIRIC EpiCURE"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006331","name":"Cancerop\u00f4le PACA","doi-asserted-by":"publisher","award":["Recherche et Innovation en Canc\u00e9"],"award-info":[{"award-number":["Recherche et Innovation en Canc\u00e9"]}],"id":[{"id":"10.13039\/501100006331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006331","name":"Cancerop\u00f4le PACA","doi-asserted-by":"publisher","award":["Rologie-RIC-01-IGR and 2017-1-EMERG-72"],"award-info":[{"award-number":["Rologie-RIC-01-IGR and 2017-1-EMERG-72"]}],"id":[{"id":"10.13039\/501100006331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Desmoplastic small round cell tumor (DSRCT) is an aggressive sarcoma subtype that is driven by the EWS\u2013WT1 chimeric transcription factor. The prognosis for DSRCT is poor, and major advances in treating DSRCT have not occurred for over two decades. To identify effective therapeutic approaches to target DSRCT, we conducted a high-throughput drug sensitivity screen in a DSRCT cell line assessing chemosensitivity profiles for 79 small-molecule inhibitors. DSRCT cells were sensitive to PARP inhibitors (PARPi) and ataxia\u2013telangiectasia and Rad3\u2013related inhibitors (ATRi), as monotherapies and in combination. These effects were recapitulated using multiple clinical PARPi and ATRi in three biologically distinct, clinically relevant models of DSRCT, including cell lines, a patient-derived xenograft\u2013derived organoid model, and a cell line\u2013derived xenograft mouse model. Mechanistically, exposure to a combination of PARPi and ATRi caused increased DNA damage, G2\u2013M checkpoint activation, micronuclei accumulation, replication stress, and R-loop formation. EWS\u2013WT1 silencing abrogated these phenotypes and was epistatic with exogenous expression of the R-loop resolution enzyme RNase H1 in reversing sensitivity to PARPi and ATRi monotherapies. The combination of PARPi and ATRi also induced EWS\u2013WT1\u2013dependent cell-autonomous activation of the cyclic GMP\u2013AMP synthase\u2013stimulator of IFN genes innate immune pathway and cell-surface expression of PD-L1. Taken together, these findings point toward a role for EWS\u2013WT1 in generating R-loop\u2013dependent replication stress that leads to a targetable vulnerability, providing a rationale for the clinical assessment of PARPi and ATRi in DSRCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>EWS\u2013WT1, the unique oncogenic driver of desmoplastic small round cell tumors, confers sensitivity to PARP and ATR inhibitors, supporting the potential of these drugs in treating patients with this aggressive sarcoma subtype.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-23-3603","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T12:21:13Z","timestamp":1729081273000},"page":"154-170","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors"],"prefix":"10.1158","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9199-8149","authenticated-orcid":false,"given":"Asuka","family":"Kawai-Kawachi","sequence":"first","affiliation":[{"name":"1The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Universit\u00e9 Paris-Saclay, Gustave Roussy, Villejuif, France."},{"name":"2Cancer RNA Research Unit, National Cancer Center Research Institute, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6743-7714","authenticated-orcid":false,"given":"Madison M.","family":"Lenormand","sequence":"additional","affiliation":[{"name":"1The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Universit\u00e9 Paris-Saclay, Gustave Roussy, Villejuif, France."},{"name":"3Department of Genomes and Genetics, Institut Pasteur, CNRS UMR3525, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4306-6635","authenticated-orcid":false,"given":"Cl\u00e9mence","family":"Astier","sequence":"additional","affiliation":[{"name":"1The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Universit\u00e9 Paris-Saclay, Gustave Roussy, Villejuif, France."},{"name":"4Universit\u00e9 Paris-Saclay, Universit\u00e9 Paris-Sud XI, Facult\u00e9 de M\u00e9dicine, Le Kremlin Bic\u00eatre, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9788-7471","authenticated-orcid":false,"given":"No\u00e9","family":"Herbel","sequence":"additional","affiliation":[{"name":"1The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Universit\u00e9 Paris-Saclay, Gustave Roussy, Villejuif, France."},{"name":"4Universit\u00e9 Paris-Saclay, Universit\u00e9 Paris-Sud XI, Facult\u00e9 de M\u00e9dicine, Le Kremlin Bic\u00eatre, France."},{"name":"5Drug Development Department, DITEP, Gustave Roussy, Villejuif, France."},{"name":"6Sarcoma Committee, Gustave Roussy, Villejuif, France."},{"name":"7Viroxis SAS Biotech, Gustave Roussy, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0403-7735","authenticated-orcid":false,"given":"Meritxell B.","family":"Cutrona","sequence":"additional","affiliation":[{"name":"8Organoid Core Facility, Gustave Roussy, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8172-5876","authenticated-orcid":false,"given":"Carine","family":"Ngo","sequence":"additional","affiliation":[{"name":"1The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Universit\u00e9 Paris-Saclay, Gustave Roussy, Villejuif, France."},{"name":"6Sarcoma Committee, Gustave Roussy, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7492-0879","authenticated-orcid":false,"given":"Marl\u00e8ne","family":"Garrido","sequence":"additional","affiliation":[{"name":"1The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Universit\u00e9 Paris-Saclay, Gustave Roussy, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0355-4474","authenticated-orcid":false,"given":"Thomas","family":"Eychenne","sequence":"additional","affiliation":[{"name":"1The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Universit\u00e9 Paris-Saclay, Gustave Roussy, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4782-6430","authenticated-orcid":false,"given":"Nicolas","family":"Dorvault","sequence":"additional","affiliation":[{"name":"1The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Universit\u00e9 Paris-Saclay, Gustave Roussy, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3110-8880","authenticated-orcid":false,"given":"Laetitia","family":"Bordelet","sequence":"additional","affiliation":[{"name":"9Experimental and Translational Pathology (PETRA) Platform, AMMICa Unit (CNRS Unit UMS 3655, Inserm Unit US 23), Gustave Roussy, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8571-3111","authenticated-orcid":false,"given":"Feifei","family":"Song","sequence":"additional","affiliation":[{"name":"10The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3076-4497","authenticated-orcid":false,"given":"Ryme","family":"Bouyakoub","sequence":"additional","affiliation":[{"name":"8Organoid Core Facility, Gustave Roussy, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7922-2396","authenticated-orcid":false,"given":"Anastasia","family":"Loktev","sequence":"additional","affiliation":[{"name":"11Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1779-7178","authenticated-orcid":false,"given":"Antonio","family":"Romo-Morales","sequence":"additional","affiliation":[{"name":"11Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7893-3116","authenticated-orcid":false,"given":"Cl\u00e9mence","family":"Henon","sequence":"additional","affiliation":[{"name":"1The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Universit\u00e9 Paris-Saclay, Gustave Roussy, Villejuif, France."},{"name":"5Drug Development Department, DITEP, Gustave Roussy, Villejuif, France."},{"name":"6Sarcoma Committee, Gustave Roussy, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5472-4616","authenticated-orcid":false,"given":"L\u00e9o","family":"Colmet-Daage","sequence":"additional","affiliation":[{"name":"1The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Universit\u00e9 Paris-Saclay, Gustave Roussy, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2370-3302","authenticated-orcid":false,"given":"Julien","family":"Vibert","sequence":"additional","affiliation":[{"name":"1The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Universit\u00e9 Paris-Saclay, Gustave Roussy, Villejuif, France."},{"name":"5Drug Development Department, DITEP, Gustave Roussy, Villejuif, France."},{"name":"6Sarcoma Committee, Gustave Roussy, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3236-5015","authenticated-orcid":false,"given":"Marjorie","family":"Drac","sequence":"additional","affiliation":[{"name":"12Institute of Molecular Genetics, CNRS Unit UMR 5535, Universit\u00e9 de Montpellier, Montpellier, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1862-7130","authenticated-orcid":false,"given":"Rachel","family":"Brough","sequence":"additional","affiliation":[{"name":"10The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9369-6419","authenticated-orcid":false,"given":"Etienne","family":"Schwob","sequence":"additional","affiliation":[{"name":"12Institute of Molecular Genetics, CNRS Unit UMR 5535, Universit\u00e9 de Montpellier, Montpellier, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0517-0991","authenticated-orcid":false,"given":"Oliviano","family":"Martella","sequence":"additional","affiliation":[{"name":"8Organoid Core Facility, Gustave Roussy, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7841-7250","authenticated-orcid":false,"given":"Guillaume","family":"Pinna","sequence":"additional","affiliation":[{"name":"13RNA Interference Platform PARi, IRCM\/IBFJ\/CEA UMRE008, Fontenay-aux-Roses, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6748-8678","authenticated-orcid":false,"given":"Janet M.","family":"Shipley","sequence":"additional","affiliation":[{"name":"11Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0463-6554","authenticated-orcid":false,"given":"Sibylle","family":"Mittnacht","sequence":"additional","affiliation":[{"name":"14UCL Cancer Institute, University College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6146-9812","authenticated-orcid":false,"given":"Astrid","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"15Research Unit Oncology, The Healthcare Business of Merck KGaA, Darmstadt, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7476-2524","authenticated-orcid":false,"given":"Aditi","family":"Gulati","sequence":"additional","affiliation":[{"name":"10The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6761-4002","authenticated-orcid":false,"given":"Olivier","family":"Mir","sequence":"additional","affiliation":[{"name":"6Sarcoma Committee, Gustave Roussy, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8006-8659","authenticated-orcid":false,"given":"Axel","family":"Le Cesne","sequence":"additional","affiliation":[{"name":"6Sarcoma Committee, Gustave Roussy, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2331-0792","authenticated-orcid":false,"given":"Matthieu","family":"Faron","sequence":"additional","affiliation":[{"name":"6Sarcoma Committee, Gustave Roussy, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1184-6143","authenticated-orcid":false,"given":"Charles","family":"Honor\u00e9","sequence":"additional","affiliation":[{"name":"6Sarcoma Committee, Gustave Roussy, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3226-0515","authenticated-orcid":false,"given":"Christopher J.","family":"Lord","sequence":"additional","affiliation":[{"name":"10The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5417-3060","authenticated-orcid":false,"given":"Roman M.","family":"Chabanon","sequence":"additional","affiliation":[{"name":"1The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Universit\u00e9 Paris-Saclay, Gustave Roussy, Villejuif, France."},{"name":"4Universit\u00e9 Paris-Saclay, Universit\u00e9 Paris-Sud XI, Facult\u00e9 de M\u00e9dicine, Le Kremlin Bic\u00eatre, France."},{"name":"10The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5562-1857","authenticated-orcid":false,"given":"Sophie","family":"Postel-Vinay","sequence":"additional","affiliation":[{"name":"1The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Universit\u00e9 Paris-Saclay, Gustave Roussy, Villejuif, France."},{"name":"4Universit\u00e9 Paris-Saclay, Universit\u00e9 Paris-Sud XI, Facult\u00e9 de M\u00e9dicine, Le Kremlin Bic\u00eatre, France."},{"name":"5Drug Development Department, DITEP, Gustave Roussy, Villejuif, France."},{"name":"6Sarcoma Committee, Gustave Roussy, Villejuif, France."},{"name":"14UCL Cancer Institute, University College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"2026042309430147100_bib1","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1158\/1078-0432.CCR-18-0202","article-title":"Multimodality treatment of desmoplastic small round cell tumor: chemotherapy and complete cytoreductive surgery improve patient survival","volume":"24","author":"Subbiah","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026042309430147100_bib2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-022-00393-3","article-title":"Small round cell sarcomas","volume":"8","author":"Cidre-Aranaz","year":"2022","journal-title":"Nat Rev Dis Primer"},{"key":"2026042309430147100_bib3","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/cancers13030498","article-title":"Desmoplastic small round cell tumor: a review of main molecular abnormalities and emerging therapy","volume":"13","author":"Mello","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026042309430147100_bib4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12881-020-01034-w","article-title":"Recurrent secondary genomic alterations in desmoplastic small round cell tumors","volume":"21","author":"Chow","year":"2020","journal-title":"BMC Med Genet"},{"key":"2026042309430147100_bib5","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1158\/1541-7786.MCR-20-0722","article-title":"Comprehensive molecular profiling of desmoplastic small round cell tumor","volume":"19","author":"Slotkin","year":"2021","journal-title":"Mol Cancer Res"},{"key":"2026042309430147100_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41698-022-00257-9","article-title":"Multi-site desmoplastic small round cell tumors are genetically related and immune-cold","volume":"6","author":"Wu","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"2026042309430147100_bib7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40880-018-0339-3","article-title":"The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial-mesenchymal transition, and immune response","volume":"38","author":"Devecchi","year":"2018","journal-title":"Cancer Commun (Lond)"},{"key":"2026042309430147100_bib8","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1073\/pnas.1700622114","article-title":"CRISPR-Cas9-guided oncogenic chromosomal translocations with conditional fusion protein expression in human mesenchymal cells","volume":"114","author":"Vanoli","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026042309430147100_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41389-020-0224-1","article-title":"Desmoplastic small round cell tumor is dependent on the EWS-WT1 transcription factor","volume":"9","author":"Gedminas","year":"2020","journal-title":"Oncogenesis"},{"key":"2026042309430147100_bib10","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41568-019-0196-7","article-title":"Targeting transcription factors in cancer - from undruggable to reality","volume":"19","author":"Bushweller","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"2026042309430147100_bib11","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/01.LAB.0000028059.92642.03","article-title":"Establishment and characterization of a novel human desmoplastic small round cell tumor cell line, JN-DSRCT-1","volume":"82","author":"Nishio","year":"2002","journal-title":"Lab Invest"},{"key":"2026042309430147100_bib12","doi-asserted-by":"crossref","first-page":"10614","DOI":"10.1038\/s41598-018-29043-z","article-title":"Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness","volume":"8","author":"Holme","year":"2018","journal-title":"Sci Rep"},{"key":"2026042309430147100_bib13","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.euo.2023.10.011","article-title":"Development of novel models of aggressive variants of castration-resistant prostate cancer","volume":"7","author":"Bigot","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"2026042309430147100_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-1-4939-2596-4_4","article-title":"Analyzing the dynamics of DNA replication in mammalian cells using DNA combing","volume":"1300","author":"Bialic","year":"2015","journal-title":"Methods Mol Biol"},{"issue":"Suppl 8","key":"2026042309430147100_bib15","doi-asserted-by":"crossref","first-page":"CT019","DOI":"10.1158\/1538-7445.AM2023-CT019","article-title":"Abstract CT019: phase I\/II study of the PARP inhibitor olaparib and ATR inhibitor ceralasertib in children with advanced malignancies: arm N of the AcS\u00e9-ESMART trial","volume":"83","author":"Gatz","year":"2023","journal-title":"Cancer Res"},{"key":"2026042309430147100_bib16","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/cts.12902","article-title":"Optimizing the therapeutic window of targeted drugs in oncology: potency-guided first-in-human studies","volume":"14","author":"Goldstein","year":"2021","journal-title":"Clin Transl Sci"},{"key":"2026042309430147100_bib17","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/1078-0432.CCR-21-1032","article-title":"Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: a phase I study","volume":"27","author":"Yap","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026042309430147100_bib18","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41416-023-02436-2","article-title":"A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours","volume":"130","author":"Burris","year":"2024","journal-title":"Br J Cancer"},{"key":"2026042309430147100_bib19","doi-asserted-by":"crossref","first-page":"109781","DOI":"10.1016\/j.isci.2024.109781","article-title":"Sarcoma_CellminerCDB: a tool to interrogate the genomic and functional characteristics of a comprehensive collection of sarcoma cell lines","volume":"27","author":"Tlemsani","year":"2024","journal-title":"iScience"},{"key":"2026042309430147100_bib20","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s00432-020-03211-z","article-title":"Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo","volume":"146","author":"van Erp","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026042309430147100_bib21","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1038\/s41467-018-03917-2","article-title":"Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance","volume":"9","author":"Pettitt","year":"2018","journal-title":"Nat Commun"},{"key":"2026042309430147100_bib22","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res"},{"key":"2026042309430147100_bib23","doi-asserted-by":"crossref","first-page":"362ps17","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci Transl Med"},{"key":"2026042309430147100_bib24","doi-asserted-by":"crossref","first-page":"101582","DOI":"10.1016\/j.xcrm.2024.101582","article-title":"Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in DSRCTs","volume":"5","author":"Henon","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026042309430147100_bib25","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1200\/JCO.2007.11.6103","article-title":"Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study","volume":"25","author":"Bomgaars","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"2026042309430147100_bib26","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.2019.37.15_suppl.3095","article-title":"A phase I\/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer","volume":"37","author":"Banerji","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026042309430147100_bib27","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jpba.2017.08.037","article-title":"LC-MS\/MS assay for the quantitation of the ATR kinase inhibitor VX-970 in human plasma","volume":"146","author":"Kiesel","year":"2017","journal-title":"J Pharm Biomed Anal"},{"key":"2026042309430147100_bib28","doi-asserted-by":"crossref","first-page":"19103","DOI":"10.1038\/srep19103","article-title":"3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained","volume":"6","author":"Zanoni","year":"2016","journal-title":"Sci Rep"},{"key":"2026042309430147100_bib29","doi-asserted-by":"crossref","first-page":"e101654","DOI":"10.15252\/embj.2019101654","article-title":"Xenograft and organoid model systems in cancer research","volume":"38","author":"Bleijs","year":"2019","journal-title":"EMBO J"},{"key":"2026042309430147100_bib30","doi-asserted-by":"crossref","first-page":"1048709","DOI":"10.3389\/fcell.2022.1048709","article-title":"Desmoplastic small round cell tumor cancer stem cell-like cells resist chemotherapy but remain dependent on the EWSR1-WT1 oncoprotein","volume":"10","author":"Magrath","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"2026042309430147100_bib31","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1021\/mp800047v","article-title":"3-D tumor model for in vitro evaluation of anticancer drugs","volume":"5","author":"Horning","year":"2008","journal-title":"Mol Pharm"},{"key":"2026042309430147100_bib32","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.molcel.2016.12.007","article-title":"Coupling of homologous recombination and the checkpoint by ATR","volume":"65","author":"Buisson","year":"2017","journal-title":"Mol Cell"},{"key":"2026042309430147100_bib33","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"2026042309430147100_bib34","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"2026042309430147100_bib35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","article-title":"Targeting replication stress in cancer therapy","volume":"22","author":"da Costa","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"2026042309430147100_bib36","first-page":"3522","article-title":"Molecular heterogeneity and function of EWS-WT1 fusion transcripts in desmoplastic small round cell tumors","volume":"6","author":"Liu","year":"2000","journal-title":"Clin Cancer Res"},{"key":"2026042309430147100_bib37","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature25748","article-title":"EWS-FLI1 increases transcription to cause R-Loops and block BRCA1 repair in Ewing sarcoma","volume":"555","author":"Gorthi","year":"2018","journal-title":"Nature"},{"key":"2026042309430147100_bib38","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41580-022-00474-x","article-title":"Sources, resolution and physiological relevance of R-loops and RNA-DNA hybrids","volume":"23","author":"Petermann","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026042309430147100_bib39","doi-asserted-by":"crossref","first-page":"13087","DOI":"10.1038\/ncomms13087","article-title":"Increased global transcription activity as a mechanism of replication stress in cancer","volume":"7","author":"Kotsantis","year":"2016","journal-title":"Nat Commun"},{"key":"2026042309430147100_bib40","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1016\/j.molcel.2022.07.011","article-title":"Mitotic DNA synthesis is caused by transcription-replication conflicts in BRCA2-deficient cells","volume":"82","author":"Groelly","year":"2022","journal-title":"Mol Cell"},{"key":"2026042309430147100_bib41","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1158\/0008-5472.CAN-21-0628","article-title":"PBRM1 deficiency confers synthetic lethality to DNA repair inhibitors in cancer","volume":"81","author":"Chabanon","year":"2021","journal-title":"Cancer Res"},{"key":"2026042309430147100_bib42","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/s41588-021-00867-2","article-title":"The SWI\/SNF chromatin remodeling complex helps resolve R-loop-mediated transcription-replication conflicts","volume":"53","author":"Bayona-Feliu","year":"2021","journal-title":"Nat Genet"},{"key":"2026042309430147100_bib43","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41576-019-0151-1","article-title":"DNA sensing by the cGAS-STING pathway in health and disease","volume":"20","author":"Motwani","year":"2019","journal-title":"Nat Rev Genet"},{"key":"2026042309430147100_bib44","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","article-title":"The cGAS-STING pathway and cancer","volume":"3","author":"Samson","year":"2022","journal-title":"Nat Cancer"},{"key":"2026042309430147100_bib45","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1172\/JCI123319","article-title":"PARP inhibition enhances tumor cell\u2013intrinsic immunity in ERCC1-deficient non\u2013small cell lung cancer","volume":"129","author":"Chabanon","year":"2019","journal-title":"J Clin Invest"},{"key":"2026042309430147100_bib46","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov"},{"key":"2026042309430147100_bib47","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","article-title":"PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer","volume":"25","author":"Ding","year":"2018","journal-title":"Cell Rep"},{"key":"2026042309430147100_bib48","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1038\/s41467-019-11048-5","article-title":"BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors","volume":"10","author":"Reisl\u00e4nder","year":"2019","journal-title":"Nat Commun"},{"key":"2026042309430147100_bib49","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/s41598-019-38534-6","article-title":"Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models","volume":"9","author":"Wang","year":"2019","journal-title":"Sci Rep"},{"key":"2026042309430147100_bib50","doi-asserted-by":"crossref","first-page":"e104036","DOI":"10.15252\/embj.2019104036","article-title":"ATR inhibition potentiates ionizing radiation-induced interferon response via cytosolic nucleic acid-sensing pathways","volume":"39","author":"Feng","year":"2020","journal-title":"EMBO J"},{"key":"2026042309430147100_bib51","doi-asserted-by":"crossref","first-page":"e61520","DOI":"10.1371\/journal.pone.0061520","article-title":"A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity","volume":"8","author":"Pettitt","year":"2013","journal-title":"PLoS One"},{"key":"2026042309430147100_bib52","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-18-2728","article-title":"Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models","volume":"25","author":"Lowery","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"Suppl 16","key":"2026042309430147100_bib53","doi-asserted-by":"crossref","first-page":"11503","DOI":"10.1200\/JCO.2022.40.16_suppl.11503","article-title":"A phase I\/II study of prexasertib in combination with irinotecan in patients with relapsed\/refractory desmoplastic small round cell tumor and rhabdomyosarcoma","volume":"40","author":"Slotkin","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026042309430147100_bib54","first-page":"PO.20.00439","article-title":"Ceralasertib-mediated ATR inhibition combined with olaparib in advanced cancers harboring DNA damage response and repair alterations (olaparib combinations)","volume":"5","author":"Mahdi","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"2026042309430147100_bib55","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1158\/0008-5472.CAN-11-3648","article-title":"PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma","volume":"72","author":"Brenner","year":"2012","journal-title":"Cancer Res"},{"key":"2026042309430147100_bib56","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2020.04.038","article-title":"Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration","volume":"136","author":"Pearson","year":"2020","journal-title":"Eur J Cancer"},{"key":"2026042309430147100_bib57","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1158\/1541-7786.MCR-18-0575","article-title":"The antitumor drugs trabectedin and lurbinectedin induce transcription-dependent replication stress and genome instability","volume":"17","author":"Tumini","year":"2019","journal-title":"Mol Cancer Res"},{"key":"2026042309430147100_bib58","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(18)30438-8","article-title":"Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group","volume":"19","author":"Grignani","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026042309430147100_bib59","doi-asserted-by":"crossref","first-page":"844250","DOI":"10.3389\/fonc.2022.844250","article-title":"DNA damage response and repair genes in advanced bone and soft tissue sarcomas: an 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination","volume":"12","author":"Merlini","year":"2022","journal-title":"Front Oncol"},{"key":"2026042309430147100_bib60","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41568-021-00386-6","article-title":"Targeting the DNA damage response in immuno-oncology: developments and opportunities","volume":"21","author":"Chabanon","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"2026042309430147100_bib61","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jtho.2022.07.074","article-title":"OA15.05 HUDSON: an open-label, multi-drug, biomarker-directed phase 2 study in NSCLC patients who progressed on anti-PD-(L)1 therapy","volume":"17","author":"Besse","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"Suppl 8","key":"2026042309430147100_bib62","doi-asserted-by":"crossref","first-page":"CT039","DOI":"10.1158\/1538-7445.AM2023-CT039","article-title":"Abstract CT039: immunomodulatory effects of ceralasertib in combination with durvalumab in patients with NSCLC and progression on anti-PD-(L)1 treatment (HUDSON, NCT03334617)","volume":"83","author":"Iyer","year":"2023","journal-title":"Cancer Res"},{"key":"2026042309430147100_bib63","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.annonc.2021.10.009","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy","volume":"33","author":"Kim","year":"2022","journal-title":"Ann Oncol"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-23-3603\/3507418\/can-23-3603.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/85\/1\/154\/3527488\/can-23-3603.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/85\/1\/154\/3527488\/can-23-3603.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T13:43:17Z","timestamp":1776951797000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/85\/1\/154\/750632\/Replication-Stress-Is-an-Actionable-Genetic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,10,16]]},"published-print":{"date-parts":[[2025,1,2]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-23-3603","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.28122649","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.28122661","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.28122640","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.28122652","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.28122643","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.28122655","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.28122646","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.28122658","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.7606507","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,16]]}}}